Virpax Pharmaceuticals Files S-1/A Amendment
| Field | Detail |
|---|---|
| Company | Virpax Pharmaceuticals, Inc. |
| Form Type | S-1/A |
| Filed Date | Mar 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1a, pharmaceuticals, securities-offering
TL;DR
Virpax S-1/A filed - looks like they're raising cash.
AI Summary
Virpax Pharmaceuticals, Inc. filed an amendment (S-1/A) on March 25, 2025, to its registration statement. The company, incorporated in Delaware with its principal executive offices in Berwyn, PA, is seeking to register securities under the Securities Act of 1933. The filing details include its IRS Employer Identification No. 82-1510982 and SEC file number 333-285862.
Why It Matters
This filing indicates Virpax Pharmaceuticals is moving forward with a securities offering, which could provide capital for its operations and drug development pipeline.
Risk Assessment
Risk Level: medium — S-1 filings generally indicate a company is seeking to raise capital, which can be a positive sign, but the success and terms of such offerings carry inherent risks.
Key Numbers
- 333-285862 — SEC File Number (Identifies the specific registration filing with the SEC.)
- 2834 — SIC Code (Indicates the company operates in the Pharmaceutical Preparations industry.)
Key Players & Entities
- Virpax Pharmaceuticals, Inc. (company) — Registrant
- 333-285862 (dollar_amount) — SEC File Number
- 20250325 (date) — Filing Date
- Jatinder Dhaliwal (person) — Chief Executive Officer
- 1055 Westlakes Drive, Suite 300 Berwyn, PA 19312 (location) — Principal Executive Offices
FAQ
What is the purpose of this S-1/A filing?
This is an amendment to a registration statement filed under the Securities Act of 1933, indicating the company is preparing to offer securities.
When was this amendment filed?
The amendment was filed on March 25, 2025.
What is Virpax Pharmaceuticals, Inc.'s primary business?
The company is classified under Standard Industrial Classification code 2834, which is Pharmaceutical Preparations.
Who is the CEO of Virpax Pharmaceuticals?
Jatinder Dhaliwal is listed as the Chief Executive Officer.
Where are Virpax Pharmaceuticals' principal executive offices located?
The principal executive offices are located at 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on March 25, 2025 by Jatinder Dhaliwal regarding Virpax Pharmaceuticals, Inc..